No Data
Paulette: 2024 Annual Results Forecast
Guangdong Biolight Meditech (300246.SZ) holding subsidiary Suzhou Junkang received a government subsidy of 60.43 million yuan.
Guangdong Biolight Meditech (300246.SZ) announced that the company's controlling subsidiary, Suzhou Juncang Medical Technology Co., Ltd. (referred to as "Suz...
Guangdong Biolight Meditech (300246.SZ): In the first half of the year, the revenue from the health monitoring sector was 0.133 billion yuan, accounting for approximately 25% of the total revenue.
Gelonghui November 19th | Guangdong Biolight Meditech (300246.SZ) stated in investor relations that, as an example in the first half of 2024, the company's health monitoring sector sales revenue was 133.3011 million yuan, accounting for approximately 25% of the revenue; blood purification sector sales revenue was 398.564 million yuan, accounting for approximately 74% of the revenue.
guangdong biolight meditech (300246.SZ): The self-developed PD600 peritoneal hemodialysis equipment has obtained the "Medical Instruments Registration Certificate".
Gelonghui November 19th | Guangdong Biolight Meditech (300246.SZ) stated in investor relations that in recent years, the company has actively laid out in the field of peritoneal dialysis (PD). The self-developed PD600 peritoneal dialysis equipment has obtained the "Medical Instruments Registration Certificate", with a complete treatment mode, equipped with an internet of things system. It can achieve remote monitoring, automatic operation, with an integrated body design, lightweight and convenient for patients to use at home. It also features intelligent voice, video operation guidance, multi-device data collection, Bluetooth transmission, and other practical functions and designs. The disposable peritoneal dialysis membranes used with the company's peritoneal dialysis equipment.
Guangdong biolight meditech (300246.SZ): Export revenue mainly consists of income from medical monitor products.
On November 19th, Gelonghui reported that Guangdong Biolight Meditech (300246.SZ) stated in its investor relations that for the previous year as an example, the company's export revenue in 2023 was 0.248 billion yuan, accounting for about 21% of the revenue; domestic sales revenue was 0.93 billion yuan, accounting for about 78% of the revenue (data rounded). The company's export revenue mainly comes from medical monitor product revenue, and there is also export business for hemodialysis series products, including blood dialysis devices, dialyzers, and dialysis fluid filters, which have already been sold overseas. Currently, the company's main export products have obtained EU CE certification, USA FDA 510(k) approval.
Guangdong Biolight Meditech (300246.SZ): In 2023, the company launched a new series of products including the S series infusion pumps, electronic urine measuring devices, and telemetry monitoring systems.
On November 19, Glen Report announced that Guangdong Biolight Meditech (300246.SZ) stated in investor relations that the company continues to adhere to the high-end route, focusing on the core pain points of medical care, with a focus on deepening the field of critical care, enriching surgical anesthesia and ICU application solutions, and further improving the category and structure of the company's medical monitor products. The competitiveness of the company's monitoring products is increasingly enhanced, with high-end medical monitors featuring several unique parameters, industry-leading anti-electrosurgical interference technology to address key pain points in the surgical anesthesia field, practical additional functions such as equipment management and fluid management, voice interaction capabilities, integration with the internet of things system, and information visualization.
The Market Doesn't Like What It Sees From Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) Revenues Yet As Shares Tumble 26%